ImmunityBio, Inc. (NASDAQ: IBRX) announced preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. The company reported preliminary net product revenue of approximately $38.3 million for the fourth quarter of 2025, representing a 20% increase over the $31.8 million recorded in the third quarter of 2025 and a 431% increase compared to the same period in 2024. For the full year, preliminary net product revenue reached $113 million, reflecting a 700% year-over-year increase. ImmunityBio also reported a 54% quarter-over-quarter unit volume growth rate during fiscal year 2025. As of December 31, 2025, the company had an estimated $242.8 million in cash, cash equivalents, and marketable securities. The company attributed this growth to increased adoption of ANKTIVA and highlighted recent regulatory approvals in Saudi Arabia, the U.S., the U.K., and conditional approval in the EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115898106) on January 15, 2026, and is solely responsible for the information contained therein.